Nomination of Christophe Thurieau as an independent member of OPM Board of Directors

Nomination of Christophe Thurieau as an independent member of OPM Board of Directors

Dijon (France), March 4, 2025, at 5:45 pm CET– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the appointment of Christophe Thurieau, Executive Director Research at Servier, as a member of the Board of Directors.